Antisense Oligonucleotide Therapeutics Pipeline Insight

DelveInsight’s “Antisense Oligonucleotide Therapeutics Pipeline Insight 2026” report provides comprehensive insights about 150+ companies and 200+ pipeline drugs in the Antisense Oligonucleotide Therapeutics pipeline landscape. It covers pipeline drug profiles, including clinical and nonclinical stage products. The report also provides therapeutic assessment by product type, stage, route of administration, and molecule type. Additionally, it highlights inactive pipeline products in this space.

Geography Covered

• • Global coverage

Antisense Oligonucleotide Disease Understanding

Antisense Oligonucleotide Overview

Aberrant protein expression or metabolism underlies a wide range of severe diseases, and since proteins are ultimately translated from messenger RNA (mRNA), targeting RNA provides a direct strategy to modulate disease-causing proteins. Advances in RNA biology have further expanded this approach by revealing the regulatory roles of non-coding RNAs, including microRNAs, transfer RNA-derived small RNAs, pseudogenes, PIWI-interacting RNAs, long non-coding RNAs, and circular RNAs, all of which contribute to gene expression control. This has established antisense oligonucleotides (ASOs) as a therapeutic platform capable of targeting pre-mRNA, mRNA, or non-coding RNAs through sequence-specific Watson–Crick base pairing, enabling precise modulation of pathogenic gene expression.

Unlike conventional small-molecule drugs, ASOs offer flexible and highly specific RNA targeting, making them particularly valuable for rare and genetic disorders. Continued advances in chemical modifications and delivery technologies have significantly enhanced their stability, efficacy, and clinical applicability. The growing success of nucleic acid-based therapeutics, including recent regulatory approvals, has further accelerated interest in the field, with multiple ASO candidates now in clinical development across diverse disease areas such as neurological, metabolic, cardiovascular, inflammatory, and infectious disorders.

Antisense oligonucleotides (ASOs) were first shown to inhibit gene expression by binding complementary mRNA through Watson–Crick base pairing, enabling sequence-specific regulation. Their mechanisms of action are broadly divided into RNA degradation and RNA modulation. In RNase H1-mediated degradation, ASOs form DNA–RNA hybrids that trigger enzymatic cleavage of the target RNA, a mechanism commonly used by approved therapies, with gapmer designs enhancing stability and activity. RNA interference similarly silences genes through Argonaute 2 within the RNA-induced silencing complex, which cleaves target mRNA guided by small interfering RNA.

In contrast, steric-blocking ASOs inhibit gene expression without RNA degradation by physically preventing ribosome assembly or RNA–protein interactions and can also disrupt microRNA function. ASOs may additionally modulate pre-mRNA splicing by promoting exon skipping or inclusion to restore or alter protein production.

The clinical application of antisense oligonucleotides (ASOs) has long been limited by challenges in efficient and targeted delivery, prompting the development of multiple delivery strategies. Enhanced stabilization chemistry has been widely used for small interfering RNA delivery, particularly through conjugation with N-acetylgalactosamine, which enables selective uptake by hepatocytes via the asialoglycoprotein receptor while also improving stability in biological fluids and reducing immune activation.

Nanoparticle-based systems, including polymeric carriers such as PLGA, PBAE, and PEI, have also been explored. While cationic polymers like PBAE and PEI enhance cellular uptake through endosomal escape mechanisms, their clinical translation has been constrained by toxicity and non-specific interactions. PLGA offers improved biocompatibility and regulatory acceptance.

Lipid-based platforms, including liposomes, lipoplexes, and lipid nanoparticles, provide another widely used approach. Polyethylene glycol modification extends circulation time and facilitates tumor accumulation via the enhanced permeability and retention effect, as exemplified by approved lipid nanoparticle-based siRNA therapeutics.

MicroRNAs (miRNAs) are short non-coding RNAs that regulate key processes involved in cell identity, development, and gene expression, and their dysregulation is linked to a wide range of malignant and non-malignant diseases. Antisense oligonucleotides have been developed to selectively inhibit disease-associated miRNAs by binding to complementary sequences and preventing their functional activity.

A notable example is miravirsen, an LNA- and phosphorothioate-modified oligonucleotide targeting miR-122 for hepatitis C virus infection, although its clinical development was limited by safety concerns. Another approach includes antimiR-21 (RG-012), developed for Alport syndrome to slow renal fibrosis progression and granted orphan drug designation in the United States and Europe.

Oncogenic miRNAs have also been therapeutically targeted, such as miR-155, which is frequently upregulated in lymphomas. Cobomarsen (MRG-106), an LNA-based inhibitor of miR-155, is currently under clinical evaluation for T-cell lymphomas. These strategies exploit the miRNA biogenesis pathway, in which primary miRNAs are processed into precursor and mature forms that are incorporated into the RNA-induced silencing complex with Argonaute proteins, enabling sequence-specific regulation of target mRNAs through translational repression or degradation, thereby providing a mechanistic basis for antisense-mediated miRNA inhibition.

“Antisense Oligonucleotide Therapeutics Pipeline Insight 2026” report by DelveInsight outlays comprehensive insights into the present scenario and growth prospects across the indication. A detailed picture of the Antisense Oligonucleotide Therapeutics pipeline landscape is provided, which includes the disease overview and treatment guidelines. The assessment section of the report includes an in-depth commercial and clinical assessment of pipeline products under development.

The Antisense Oligonucleotide Therapeutics Pipeline report provides detailed drug descriptions, including mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other product-related details.

Antisense Oligonucleotide Pipeline Report Highlights

• • Companies and academic institutions are actively working to assess challenges and identify opportunities that could influence Antisense Oligonucleotide Therapeutics R&D.
• • Therapies under development are focused on novel approaches to treat or improve Antisense Oligonucleotide Therapeutics.

Antisense Oligonucleotide Emerging Drugs Analysis

This segment of the report provides detailed analysis of various drugs in different stages of clinical development, including Phase III, Phase II, Phase I, Preclinical, and Discovery stages. It also provides insights into clinical trial details, pharmacological action, agreements and collaborations, as well as the latest news and press releases.

Antisense Oligonucleotide Emerging Drugs

DYNE-101: Dyne Therapeutics

DYNE-101 is Dyne’s therapeutic candidate being developed for people living with myotonic dystrophy type 1 (DM1). DYNE-101 consists of an antigen-binding fragment antibody (Fab) conjugated to an antisense oligonucleotide (ASO) to enable targeted muscle tissue delivery with the goal of reducing toxic DMPK RNA in the nucleus, releasing splicing proteins, allowing normal mRNA processing and translation of normal proteins, and potentially stopping or reversing the disease. Currently, the drug is in Phase III clinical development for myotonic dystrophy.

Pelacarsen: Novartis

Pelacarsen (TQJ230), also known as IONIS-APO(a)-LRx and AKCEA-APO(a)-LRx, is an investigational antisense medicine designed to reduce apolipoprotein(a) in the liver to lower lipoprotein(a) levels. Elevated Lp(a) is recognized as an independent genetic cause of coronary artery disease, stroke, heart attack, and peripheral arterial disease. The drug is currently in Phase III development for Hyperlipoproteinaemia and Atherosclerosis.

AHB-137: Ausper Bio

AHB-137 is a novel unconjugated antisense oligonucleotide developed through AusperBio’s proprietary Med-Oligo™ ASO platform for chronic hepatitis B treatment. The dual-mechanism ASO is currently undergoing Phase Ib and Phase II clinical trials and is advancing toward functional cure strategies for HBV infection. The drug is presently in Phase III stage development for Chronic Hepatitis B.

Tonlamarsen: Kardigan

Tonlamarsen (formerly ION904) is an investigational angiotensinogen-targeted therapy designed to disrupt the pathological cycle of acute severe hypertension. The therapy aims to lower blood pressure and reduce the risk of organ damage and cardiovascular events. The drug is in Phase II/III development for Hypertension.

WVE-N531: Wave Life Sciences

WVE-N531 is an exon-skipping oligonucleotide being developed as a disease-modifying therapy for Duchenne muscular dystrophy patients amenable to exon 53 skipping. It utilizes Wave’s PN backbone chemistry modifications and has received Orphan Drug and Rare Pediatric Disease designations from the US FDA. The drug is currently in Phase II clinical evaluation.

ION717: Ionis Pharmaceuticals

ION717 is an investigational ASO therapy designed to lower levels of prion protein (PrP) in patients with prion diseases. Administered intrathecally, the therapy is currently under evaluation in a Phase I/IIa clinical trial for safety, tolerability, pharmacokinetics, and pharmacodynamics.

VCA-894A: Vanda Pharmaceuticals

VCA-894A is a novel ASO therapeutic developed for Charcot-Marie-Tooth disease Type 2S (CMT2S), an ultra-rare inherited neuromuscular disorder. It is designed to target a cryptic splice site variant in the IGHMBP2 gene to restore normal gene expression. The therapy is in Phase I/II clinical development.

QRL-201: QurAlis Corporation

QRL-201 is an investigational RNA-targeted therapy for Amyotrophic Lateral Sclerosis (ALS). It aims to restore STATHMIN-2 (STMN2) expression, which is significantly reduced in ALS patients. The therapy has received clinical trial authorizations in Canada, the European Union, and the United Kingdom and is currently in Phase I/II development.

AX-0810: ProQR

AX-0810 is an investigational therapy being developed for cholestatic disorders, a group of liver diseases characterized by impaired bile flow and progressive liver injury. The therapy is designed to address underlying pathological mechanisms associated with bile acid accumulation and hepatocellular damage. It is currently in Phase I clinical development.

SECN-15: Secarna Pharmaceuticals

SECN-15 is a potential first-in-class antisense oligonucleotide therapy targeting Neuropilin-1 (NRP1) for solid tumors. The program aims to improve anti-tumor immune responses and enhance the efficacy of immune checkpoint inhibitors. Preclinical studies demonstrated strong NRP1 knockdown and improved anti-tumor activity. The therapy is currently in preclinical development.

Further product details are provided in the report.

Antisense Oligonucleotide Drug Therapeutic Assessment

This segment of the report provides insights into different Antisense Oligonucleotide Therapeutics drugs segmented on the basis of the following parameters:

Major Antisense Oligonucleotide Players in Antisense Oligonucleotide  

• • Approximately 150+ key companies are developing therapies for Antisense Oligonucleotide Therapeutics.
• • Dyne Therapeutics has one of the most advanced pipeline candidates currently in Phase III development.

Antisense Oligonucleotide Clinical Trial Phases

The report covers around 200+ products under different stages of clinical development, including:

• • Late-stage products (Phase III)
• • Mid-stage products (Phase II)
• • Early-stage products (Phase I)
• • Preclinical and Discovery stage candidates
• • Discontinued and inactive candidates

Antisense Oligonucleotide Drug Route of Administration

The pipeline report provides therapeutic assessment based on route of administration categories such as:

• • Oral
• • Intravenous
• • Subcutaneous
• • Parenteral
• • Topical

Antisense Oligonucleotide Product Molecule Type

Products have been categorized under different molecule types, including:

• • Recombinant fusion proteins
• • Small molecules
• • Monoclonal antibodies
• • Peptides
• • Polymers
• • Gene therapies

Antisense Oligonucleotide Product Type

Drugs have been categorized into:

• • Mono therapies
• • Combination therapies
• • Mono/Combination therapies

Antisense Oligonucleotide Clinical Trial Activities

The Antisense Oligonucleotide Pipeline report provides insights into Antisense Oligonucleotide Clinical Trials within Phase III, II, I, preclinical, and discovery stages. It also analyzes key companies involved in developing Antisense Oligonucleotide Therapeutics drugs.

Antisense Oligonucleotide Pipeline Development Activities

The Antisense Oligonucleotide Clinical Trial analysis report includes detailed information related to collaborations, acquisitions, mergers, licensing activities, and comprehensive therapeutic assessments of emerging drugs.

Antisense Oligonucleotide Pipeline Report Insights

• • Antisense Oligonucleotide Therapeutics Pipeline Analysis
• • Therapeutic Assessment
• • Unmet Needs
• • Impact of Drugs

Antisense Oligonucleotide Pipeline Report Assessment

• • Pipeline Product Profiles
• • Therapeutic Assessment
• • Pipeline Assessment
• • Inactive Drugs Assessment
• • Unmet Needs

Key Questions Answered In The Antisense Oligonucleotide Pipeline Report

Current Treatment Scenario and Emerging Therapies

• • How many companies are developing Antisense Oligonucleotide Therapeutics drugs?
• • How many Antisense Oligonucleotide Therapeutics drugs are being developed by each company?
• • How many emerging drugs are in mid-stage and late-stage development?
• • What are the key collaborations, mergers and acquisitions, and licensing activities related to Antisense Oligonucleotide Therapeutics?
• • What are the recent trends, drug types, and novel technologies developed to overcome limitations of existing therapies?
• • What clinical studies are ongoing and what is their current status?
• • What key designations have been granted to emerging drugs?

Antisense Oligonucleotide Key Companies

• • Novartis
• • AusperBio
• • Otsuka Pharmaceutical
• • Biogen
• • Praxis Precision Medicines
• • Sunhawk Vision Biotech
• • Kardigan
• • Wave Life Sciences
• • Ionis Pharmaceuticals
• • Oak Hill Bio
• • Ono Pharma
• • AstraZeneca
• • NS Pharma
• • Splisense
• • Roche
• • Novo Nordisk A/S
• • Bio-Path Holdings
• • Isarna Therapeutics
• • Laboratoire Théa
• • Imvax
• • Zhejiang Haichang Biotech Co., Ltd.
• • Amber Ophthalmics
• • Lipigon Pharmaceuticals
• • Flamingo Therapeutics
• • Vanda Pharmaceuticals
• • Servier
• • Dyne Therapeutics
• • Vico Therapeutics
• • PYC Therapeutics
• • Denali Therapeutics
• • ProQR Therapeutics
• • Synaptix Bio
• • Autotelic Bio
• • Andes Biotechnologies
• • Nano MRNA

Antisense Oligonucleotide Key Products

• • Pelacarsen
• • AHB-137
• • Ulefnersen
• • BIIB115
• • PRAX-222
• • SHJ002
• • Tonlamarsen
• • WVE-N531
• • ION717
• • Rugonersen
• • Sapablursen
• • ALXN2030
• • Brogidirsen
• • SPL84
• • Tominersen
• • CDR132L
• • BP1001
• • ISTH0036
• • Ultevursen
• • IGV-001
• • WGI-0301
• • Lufepirsen
• • Lipisense
• • Danvatirsen
• • VCA-894A
• • KCNT1 ASO
• • DYNE-101
• • VO659
• • PYC-001
• • DNL628
• • AX-0810
• • SB-19642
• • ATB-320
• • ANDES-1537
• • TUG1 ASO